Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

GW Pharmaceuticals’ Sativex given positive evaluation by German health watchdog

GW Pharmaceuticals’ Sativex given positive evaluation by German health watchdog

GW Pharmaceuticals (LON:GWP) was notified by its partner Almirall that the German federal health watchdog G-BA has given a positive evaluation for the cannabis-derived Sativex treatment.

Sativex is indicated as a supplemental treatment for patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not adequately responded to other anti-spasticity medications.

The G-BA has determined that there was an indication of minor added benefit of Sativex as an add-on therapy in MS-induced spasticity, according to Almirall, its exclusive licence partner for the EU except UK.

GW managing director Justin Gover said:"This determination by the G-BA is a positive step for GW. We now look forward to our partners, Almirall, commencing price negotiations in Germany."

Nomura Code, a European investment bank focused on healthcare and clean technology, said in a note it views the latest announcement as positive for GW Pharma and its partner, as in its view there was always the possibility that the G-BA, despite the last line nature of Sativex, issued a determination of no additional benefit.

“While the benefit has been determined as minor, this is unsurprising in our view, and we believe Almirall and GW Pharmaceuticals have a reasonable basis from the perspective of subsequent pricing negotiations,” The bank said.

“For now we maintain our Neutral rating and fair value of 100-105 pence as we await final pricing determination in Germany and indications of an acceleration of uptake of Sativex in launched markets,” Nomura Code added.

The stock was last trading at 82 pence.

Sativex is also in Phase III clinical development as a treatment for cancer pain.

View full GWP profile View Profile

GW Pharmaceuticals Timeline

Related Articles

The company is utilising technology and big data to tackle the growing healthcare crisis and personalise treatment options for preventative care.
Following the disappointment of its DMD treatment over summer, Summit is leveraging its Discuva platform to develop new antibiotics, which doctors are in desperate need of
July 11 2018
Valirx raised just short of a £1mln in May to progress the clinical trial of VAL201 and to advance the pre-clinical programmes, VAL101 and VAL301.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use